| abstract |
FIELD: physics, pharmaceutics. n SUBSTANCE: invention relates to immunology, particularly to stable formulations of antibodies to the human programmed death receptor PD-1. Said formulations can be liquid or lyophilised, and contain 25-100 mg/ml antibody to human PD-1, about 70 mg/ml sucrose, about 0.2 mg/ml polysorbate 80 and about 10 mM histidine buffer at pH 5.0-6.0, where the antibody to human PD-1 is h409A11. n EFFECT: invention enables to obtain stable pharmaceutical formulations for treating patients with malignant growths or chronic viral infection. n 7 cl, 18 dwg, 6 tbl, 3 ex |